Dermatology Advisor’s Post

Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea #stockmarket #stocks #investing #businessnews #trading #daytrading #clinicaltrial

Data from the Phase III SURMOUNT-OSA study showed that Lilly's top-selling weight-loss drug Zepbound substantially improved obstructive sleep apnea symptoms in patients. The pharma will submit these data to the FDA and other global health regulatory agencies by mid-year, the pharma said. This readout also adds to the ever-expanding list of diseases that GLP-1 receptor agonists appear to be effective against. Last month, the FDA approved Novo's Wegovy to lower the risk of cardiovascular death, heart attack and stroke in overweight and obese adult patients with cardiovascular disease. Semaglutide has also shown that it can preserve kidney health in type 2 diabetes patients with chronic kidney disease. Meanwhile, Boehringer Ingelheim’s obesity hopeful survodutide demonstrated strong potential for metabolic dysfunction-associated steatohepatitis in a Phase II study. #biotech #biopharma #Zepbound #Wegovy #GLP1 #sleepapnea

An interesting article in the  Journal of the American College of Cardiology on the largest randomized clinical trial to date on the comparative effectiveness of mandibular advancement device (MAD) versus CPAP therapy for BP reduction. A tailored (personalized) approach should be taken when considering CPAP or MAD based on updated evidence, treatment feasibility, and individual characteristics for those OSA patients who have moderate-to-severe OSA, hypertension, and increased cardiovascular (CV) risk.

Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea: https://lnkd.in/e58Ah22s cc: Incannex Healthcare Inc

Another excellent way to treat chronic pain issues and improve overall health. Full stimulation of the spinal region produces a range of positive benefits including neuropeptide release of GABA that produces numerous benefits such as vascular permeability that positively impact blood pressure, respiration, and sleep cycles. #painmanagement #painrelief #longevity #longevitymedicine #functionalmedicine #sleephealth #bloodpressure #internalmedicine #pulmonology https://lnkd.in/gTE3xtDX

Lower limb edema, or swelling of the legs, can come from many causes, some harmless and some dangerous. Our doctors wanted to help our clients with stubborn edema manage it better, and to know when to call for medical help. We dug into both the medical literature AND the stuff on social media, with the goal of separating the helpful from the not helpful. Some lessons: ✅ Massage: HELPFUL. This can be super effective at resolving cases when nothing else works, especially for a specific subtype of edema called lymphedema. For these cases, it's worth connecting with the specially trained practitioners who could give you dramatically better outcomes ✅ Compression: HELPFUL. This is a mainstay in both wound clinics and million milers. They really improve venous return. You can get them in a range of pressures and lengths, including all the way up to the thigh. Quality and size matters, so don’t give up on this approach until you’ve made sure you’ve optimized for both 🛑 Drinking more water: NOT HELPFUL. Lots of websites (and as a result, AI chatbots) will tell you that drinking more water will encourage your body to flush more out, concluding you can use it to decrease edema. While it’s true that the kidney regulates water it conserves in response to how much it’s getting, this goes both ways: you pee more when you drink more but also pee less when you drink less (not retain more water when you drink less). If anything, over-drinking water without matching electrolytes can cause edema in people who otherwise don't have edema (and can worsen edema in people with edema due to kidney disease) See the full report here: https://lnkd.in/eSb8rJYU. And share with us what has worked for your edema!   (As always, do not substitute general reports like this for tailored medical advice. Ask a doctor or health expert you trust for how general advice applies to your unique scenario.)

Excited to share my recent feature in @Sleep Review about my #SLEEP2024 presentation that focused on the significance of individualizing oxybate dosing for patients with narcolepsy and idiopathic hypersomnia to help improve their outcomes and response to treatment. Check out the article here: https://lnkd.in/gS7Ka8fY

Positive results in phase 2b trial of orexin receptor agonist for narcolepsy type 1. Key takeaways: TAK-861 was investigated in a trial of 112 individuals with narcolepsy type 1 over 8 weeks. Data showed significant improvements in primary, secondary endpoints, while efficacy was also sustained. Takeda has reported positive results from a phase 2b clinical trial of an investigational, oral orexin receptor agonist for narcolepsy type 1. Link: https://lnkd.in/eBJrSwzV ------------------------- Join the bspss.org (FREE) to get online, free CPD and access to services to help suspected sleep disorder sufferers in an evidence-based way. We're all about 𝗠𝗮𝗸𝗶𝗻𝗴 𝗦𝗹𝗲𝗲𝗽 𝗔𝗰𝗰𝗲𝘀𝘀𝗶𝗯𝗹𝗲® by advancing community pharmacy sleep services to improve patient outcomes in primary care. #MakingSleepAccessible #SleepDisorders #CommunityPharmacy

💡Progesterone is like your body’s calming force, helping with sleep, mood, and even inflammation (hello, balance!). And this one’s definitely a must-read if you’ve been feeling off and wondering if it’s hormone-related. We talk a lot about estrogen, but sometimes it’s about giving progesterone some love, too. If you’re all about balancing your body, check this out and learn why both hormones need to work together. 👉 https://lnkd.in/gMiTJgnb #hormonehealth #progesterone #womenshealth #holistichealth #balanceyourbody #functionalmedicine #strongwomen #wellnessjourney #WomenInMotion #WIMN

First Effective Drug Therapy for Obstructive Sleep Apnea: Tirzepatide. Research article: https://lnkd.in/gE7JfgqG Welcome back to our channel, where we bring you the latest and most groundbreaking findings in medicine. Today, we have an exciting development in the field of sleep medicine that could change the lives of millions around the world. Researchers at the University of California, San Diego School of Medicine, along with international collaborators, have discovered the first effective drug therapy for obstructive sleep apnea (OSA). OSA is a serious sleep disorder that affects nearly 936 million people worldwide, leading to repeated interruptions in breathing during sleep and increasing the risk of cardiovascular issues. In this video, we delve into the groundbreaking study led by Dr. Atul Malhotra, exploring the use of tirzepatide, a drug originally developed for type 2 diabetes, as a potential treatment for OSA. Discover how this innovative solution could offer new hope to individuals struggling with CPAP machines and improve overall health outcomes. Don't forget to like, share, and subscribe for more groundbreaking medical news. Thanks for watching! #SleepApnea #MedicalBreakthrough #HealthNews #SleepMedicine #OSA #SleepDisorder #MedicalResearch #DrugTherapy #HealthUpdate #MedicalInnovation #UCSD #UCSDHealth #Tirzepatide #DiabetesTreatment #WeightLoss #MetabolicHealth #CardiovascularHealth #CPAPAlternative #MedicalDiscovery #HealthRevolution #SleepHealth #ObesityTreatment #MedicalScience #SleepStudy #ClinicalTrial #HealthAwareness #GlobalHealth #InnovativeMedicine #SleepWell #HealthcareInnovation #MedicalFindings #ResearchStudy #HealthcareBreakthrough #HealthEducation #SleepResearch #ChronicDisease #WellnessJourney #HealthyLiving #MedicalNewsToday #HealthUpdate2024 #PharmacyNews #Pharmaceuticals #MedicalCommunity #SleepTherapy #ObstructiveSleepApnea #HealthBreakthrough #SleepApneaTreatment #SleepDisorders #MedicalUpdates